Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Squarepoint Ops LLC

Squarepoint Ops LLC grew its stake in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 75.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,074 shares of the company’s stock after acquiring an additional 36,139 shares during the period. Squarepoint Ops LLC’s holdings in Galectin Therapeutics were worth $190,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at approximately $43,000. Rhumbline Advisers acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at approximately $44,000. Retirement Guys Formula LLC lifted its position in shares of Galectin Therapeutics by 56.9% during the 1st quarter. Retirement Guys Formula LLC now owns 33,732 shares of the company’s stock valued at $81,000 after acquiring an additional 12,232 shares during the period. Traynor Capital Management Inc. lifted its position in shares of Galectin Therapeutics by 23.5% during the 2nd quarter. Traynor Capital Management Inc. now owns 42,871 shares of the company’s stock valued at $97,000 after acquiring an additional 8,164 shares during the period. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at approximately $146,000. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on GALT shares. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, October 6th. HC Wainwright reissued a “buy” rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research note on Friday, August 16th.

Galectin Therapeutics Price Performance

Shares of GALT opened at $2.70 on Monday. The firm has a 50 day simple moving average of $2.53 and a 200-day simple moving average of $2.73. Galectin Therapeutics Inc. has a 1-year low of $1.55 and a 1-year high of $4.27. The stock has a market cap of $167.80 million, a price-to-earnings ratio of -3.65 and a beta of 0.61.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). On average, equities analysts expect that Galectin Therapeutics Inc. will post -0.79 earnings per share for the current fiscal year.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.